167 related articles for article (PubMed ID: 27131597)
41. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand.
Qin JZ; Bacon P; Chaturvedi V; Nickoloff BJ
J Invest Dermatol; 2001 Oct; 117(4):898-907. PubMed ID: 11676830
[TBL] [Abstract][Full Text] [Related]
42. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.
Zhang Z; Chen J; Ding L; Jin H; Lovell JF; Corbin IR; Cao W; Lo PC; Yang M; Tsao MS; Luo Q; Zheng G
Small; 2010 Feb; 6(3):430-7. PubMed ID: 19957284
[TBL] [Abstract][Full Text] [Related]
43. Manipulating multifaceted microbubble shell composition to target both TRAIL-sensitive and resistant cells.
Jablonowski LJ; Conover D; Teraphongphom NT; Wheatley MA
J Biomed Mater Res A; 2018 Jul; 106(7):1903-1915. PubMed ID: 29521001
[TBL] [Abstract][Full Text] [Related]
44. A multilayer hollow nanocarrier for pulmonary co-drug delivery of methotrexate and doxorubicin in the form of dry powder inhalation formulation.
Nozohouri S; Salehi R; Ghanbarzadeh S; Adibkia K; Hamishehkar H
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():752-761. PubMed ID: 30889750
[TBL] [Abstract][Full Text] [Related]
45. Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y; Tian B; Wang Y; Ding H
Med Sci Monit; 2017 Oct; 23():5096-5105. PubMed ID: 29070784
[TBL] [Abstract][Full Text] [Related]
46. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.
Sawant RM; Hurley JP; Salmaso S; Kale A; Tolcheva E; Levchenko TS; Torchilin VP
Bioconjug Chem; 2006; 17(4):943-9. PubMed ID: 16848401
[TBL] [Abstract][Full Text] [Related]
47. Lipid Nanoparticles Decorated with TNF-Related Aptosis-Inducing Ligand (TRAIL) Are More Cytotoxic than Soluble Recombinant TRAIL in Sarcoma.
Gallego-Lleyda A; De Miguel D; Anel A; Martinez-Lostao L
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757258
[TBL] [Abstract][Full Text] [Related]
48. NanoTRAIL-Oncology: A Strategic Approach in Cancer Research and Therapy.
Shi Y; Pang X; Wang J; Liu G
Adv Healthc Mater; 2018 Jun; 7(11):e1800053. PubMed ID: 29527836
[TBL] [Abstract][Full Text] [Related]
49. pH-responsive drug delivery of chitosan nanoparticles as Tamoxifen carriers for effective anti-tumor activity in breast cancer cells.
Vivek R; Nipun Babu V; Thangam R; Subramanian KS; Kannan S
Colloids Surf B Biointerfaces; 2013 Nov; 111():117-23. PubMed ID: 23787278
[TBL] [Abstract][Full Text] [Related]
50. A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy.
Wang ZQ; Liu K; Huo ZJ; Li XC; Wang M; Liu P; Pang B; Wang SJ
J Nanobiotechnology; 2015 Oct; 13():63. PubMed ID: 26427800
[TBL] [Abstract][Full Text] [Related]
51. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
52. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
Yu HP; Aljuffali IA; Fang JY
Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
[TBL] [Abstract][Full Text] [Related]
53. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
[TBL] [Abstract][Full Text] [Related]
54. Transformable liquid-metal nanomedicine.
Lu Y; Hu Q; Lin Y; Pacardo DB; Wang C; Sun W; Ligler FS; Dickey MD; Gu Z
Nat Commun; 2015 Dec; 6():10066. PubMed ID: 26625944
[TBL] [Abstract][Full Text] [Related]
55. DQAsomes as the prototype of mitochondria-targeted pharmaceutical nanocarriers: preparation, characterization, and use.
Weissig V
Methods Mol Biol; 2015; 1265():1-11. PubMed ID: 25634263
[TBL] [Abstract][Full Text] [Related]
56. Folate-decorated hydrophilic three-arm star-block terpolymer as a novel nanovehicle for targeted co-delivery of doxorubicin and Bcl-2 siRNA in breast cancer therapy.
Qian J; Xu M; Suo A; Xu W; Liu T; Liu X; Yao Y; Wang H
Acta Biomater; 2015 Mar; 15():102-16. PubMed ID: 25545322
[TBL] [Abstract][Full Text] [Related]
57. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
58. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
59. Micelles of enzymatically synthesized PEG-poly(amine-co-ester) block copolymers as pH-responsive nanocarriers for docetaxel delivery.
Zhang X; Liu B; Yang Z; Zhang C; Li H; Luo X; Luo H; Gao D; Jiang Q; Liu J; Jiang Z
Colloids Surf B Biointerfaces; 2014 Mar; 115():349-58. PubMed ID: 24398083
[TBL] [Abstract][Full Text] [Related]
60. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
